{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:03:10Z","timestamp":1789437790179,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":78,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-026-04988-2","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T02:15:54Z","timestamp":1782699354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy and safety of Ranibizumab and Aflibercept for neovascular age-related macular degeneration: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Xiaoqin","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"issue":"3","key":"4988_CR1","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","volume":"113","author":"RL Avery","year":"2006","unstructured":"Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir M, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113(3):363\u201372.e5. https:\/\/doi.org\/10.1016\/j.ophtha.2005.11.019.","journal-title":"Ophthalmology"},{"issue":"11","key":"4988_CR2","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1038\/s41433-025-03829-8","volume":"39","author":"JI Lim","year":"2025","unstructured":"Lim JI, Ko S, McAllister M, Faux N, Bawa K, Mearns E, et al. Systematic review of clinical practice guidelines for the management of neovascular age-related macular degeneration. Eye (Lond). 2025;39(11):2223\u201330. https:\/\/doi.org\/10.1038\/s41433-025-03829-8.","journal-title":"Eye (Lond)"},{"issue":"4","key":"4988_CR3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.preteyeres.2007.03.002","volume":"26","author":"UM Schmidt-Erfurth","year":"2007","unstructured":"Schmidt-Erfurth UM, Pruente C. Management of neovascular age-related macular degeneration. Prog Retin Eye Res. 2007;26(4):437\u201351. https:\/\/doi.org\/10.1016\/j.preteyeres.2007.03.002.","journal-title":"Prog Retin Eye Res"},{"issue":"8","key":"4988_CR4","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.2165\/00003495-200868080-00002","volume":"68","author":"AV Chappelow","year":"2008","unstructured":"Chappelow AV, Kaiser PK. Neovascular age-related macular degeneration: potential therapies. Drugs. 2008;68(8):1029\u201336. https:\/\/doi.org\/10.2165\/00003495-200868080-00002.","journal-title":"Drugs"},{"issue":"14","key":"4988_CR5","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419\u201331. https:\/\/doi.org\/10.1056\/NEJMoa054481.","journal-title":"N Engl J Med"},{"issue":"7","key":"4988_CR6","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/eye.2013.107","volume":"27","author":"KG Falavarjani","year":"2013","unstructured":"Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 2013;27(7):787\u201394. https:\/\/doi.org\/10.1038\/eye.2013.107.","journal-title":"Eye (Lond)"},{"key":"4988_CR7","doi-asserted-by":"publisher","unstructured":"Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Systematic Rev. 2014;8. https:\/\/doi.org\/10.1002\/14651858.CD005139.pub3.","DOI":"10.1002\/14651858.CD005139.pub3"},{"issue":"27","key":"4988_CR8","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1056\/NEJMoa042760","volume":"351","author":"ES Gragoudas","year":"2004","unstructured":"Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805\u201316. https:\/\/doi.org\/10.1056\/NEJMoa042760.","journal-title":"N Engl J Med"},{"issue":"21","key":"4988_CR9","doi-asserted-by":"publisher","first-page":"8242","DOI":"10.3390\/ijms21218242","volume":"21","author":"F Ricci","year":"2020","unstructured":"Ricci F, Bandello F, Navarra P, Staurenghi G, Stumpp M, Zarbin M. Neovascular age-related macular degeneration: therapeutic management and new-upcoming approaches. Int J Mol Sci. 2020;21(21):8242. https:\/\/doi.org\/10.3390\/ijms21218242.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4988_CR10","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology. 2020;127(5):616\u201336. https:\/\/doi.org\/10.1016\/j.ophtha.2019.11.004.","journal-title":"Ophthalmology"},{"issue":"Suppl. 1","key":"4988_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000337154","volume":"227","author":"D Veritti","year":"2012","unstructured":"Veritti D, Sarao V, Lanzetta P. Neovascular age-related macular degeneration. Ophthalmologica. 2012;227(Suppl. 1):11\u201320. https:\/\/doi.org\/10.1159\/000337154.","journal-title":"Ophthalmologica"},{"issue":"5","key":"4988_CR12","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/j.1755-3768.2007.00979.x","volume":"85","author":"UM Schmidt-Erfurth","year":"2007","unstructured":"Schmidt-Erfurth UM, Richard G, Augustin A, Aylward WG, Bandello F, Corcostegui B, et al. Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand. 2007;85(5):486\u201394. https:\/\/doi.org\/10.1111\/j.1755-3768.2007.00979.x.","journal-title":"Acta Ophthalmol Scand"},{"issue":"8","key":"4988_CR13","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","volume":"123","author":"MG Maguire","year":"2016","unstructured":"Maguire MG, Martin DF, Ying G-S, Jaffe GJ, Daniel E, Grunwald JE, et al. Group CoA-rMDTTR: five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123(8):1751\u201361. https:\/\/doi.org\/10.1016\/j.ophtha.2016.03.045.","journal-title":"Ophthalmology"},{"issue":"20","key":"4988_CR14","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"DF Martin","year":"2011","unstructured":"Martin DF, Maguire MG, Ying G, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. NEJM Evid. 2011;364(20):1897\u2013908.","journal-title":"NEJM Evid"},{"issue":"7","key":"4988_CR15","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","volume":"119","author":"U Chakravarthy","year":"2012","unstructured":"Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119(7):1399\u2013411. https:\/\/doi.org\/10.1016\/j.ophtha.2012.04.015.","journal-title":"Ophthalmology"},{"issue":"12","key":"4988_CR16","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537\u201348. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.006.","journal-title":"Ophthalmology"},{"issue":"12","key":"4988_CR17","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1016\/j.ophtha.2015.08.009","volume":"122","author":"CC Wykoff","year":"2015","unstructured":"Wykoff CC, Croft DE, Brown DM, Wang R, Payne JF, Clark L, et al. Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology. 2015;122(12):2514\u201322. https:\/\/doi.org\/10.1016\/j.ophtha.2015.08.009.","journal-title":"Ophthalmology"},{"issue":"12","key":"4988_CR18","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1136\/bjophthalmol-2015-308166","volume":"100","author":"FG Holz","year":"2016","unstructured":"Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Hykin P, et al. Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. Br J Ophthalmol. 2016;100(12):1623\u201328. https:\/\/doi.org\/10.1136\/bjophthalmol-2015-308166.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"4988_CR19","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.ajo.2014.07.006","volume":"158","author":"JJ Jung","year":"2014","unstructured":"Jung JJ, Chen CY, Mrejen S, Gallego-Pinazo R, Xu L, Marsiglia M, et al. The incidence of neovascular subtypes in newly diagnosed neovascular age-related macular degeneration. Am J Ophthalmol. 2014;158(4):769\u201379.e2. https:\/\/doi.org\/10.1016\/j.ajo.2014.07.006.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"4988_CR20","first-page":"142","volume":"15","author":"NM Bressler","year":"2002","unstructured":"Bressler NM. Early detection and treatment of neovascular age-related macular degeneration. J Am Board Fam Pract. 2002;15(2):142\u201352.","journal-title":"J Am Board Fam Pract"},{"key":"4988_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2015.07.007","volume":"50","author":"U Schmidt-Erfurth","year":"2016","unstructured":"Schmidt-Erfurth U, Waldstein SM. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res. 2016;50:1\u201324. https:\/\/doi.org\/10.1016\/j.preteyeres.2015.07.007.","journal-title":"Prog Retin Eye Res"},{"key":"4988_CR22","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.2147\/OPTH.S275977","volume":"14","author":"H Mehta","year":"2020","unstructured":"Mehta H, Kim LN, Mathis T, Zalmay P, Ghanchi F, Amoaku WM, et al. Trends in real-world neovascular AMD treatment outcomes in the UK. Clin Ophthalmol. 2020;14:3331\u201342. https:\/\/doi.org\/10.2147\/OPTH.S275977.","journal-title":"Clin Ophthalmol"},{"issue":"8","key":"4988_CR23","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1097\/00006982-200512000-00016","volume":"25","author":"D Pauleikhoff","year":"2005","unstructured":"Pauleikhoff D. Neovascular age-related macular degeneration: natural history and treatment outcomes. Retina. 2005;25(8):1065\u201384. https:\/\/doi.org\/10.1097\/00006982-200512000-00016.","journal-title":"Retina"},{"key":"4988_CR24","doi-asserted-by":"crossref","unstructured":"Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. 2008.","DOI":"10.1002\/9780470712184"},{"key":"4988_CR25","doi-asserted-by":"publisher","unstructured":"Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ. 2010;340:c221. https:\/\/doi.org\/10.1136\/bmj.c221.","DOI":"10.1136\/bmj.c221"},{"issue":"9","key":"4988_CR26","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u201305. https:\/\/doi.org\/10.1007\/s10654-010-9491-z.","journal-title":"Eur J Epidemiol"},{"issue":"4","key":"4988_CR27","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1136\/bmjebm-2022-112102","volume":"28","author":"E Flemyng","year":"2023","unstructured":"Flemyng E, Moore TH, Boutron I, Higgins JP, Hr\u00f3bjartsson A, Nejstgaard CH, et al. Using risk of bias 2 to assess results from randomised controlled trials: guidance from Cochrane. BMJ Evid Based Med. 2023;28(4):260\u201366. https:\/\/doi.org\/10.1136\/bmjebm-2022-112102.","journal-title":"BMJ Evid Based Med"},{"key":"4988_CR28","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366. https:\/\/doi.org\/10.1136\/bmj.l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"4988_CR29","doi-asserted-by":"publisher","unstructured":"Skrzypczak T, Jany A, Bugajska-Abramek E, Bogus\u0142awska J, Kowal-Lange A. A comparative study of ranibizumab and aflibercept for neovascular age-related macular degeneration: 12-month outcomes of Polish therapeutic program in non-tertiary institution. Cureus. 2021;13(6). https:\/\/doi.org\/10.7759\/cureus.15916.","DOI":"10.7759\/cureus.15916"},{"issue":"7","key":"4988_CR30","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/jop.2017.0031","volume":"33","author":"JG Garweg","year":"2017","unstructured":"Garweg JG, Gerhardt C, Kodjikian L, Pfister IB. Real-life experience with aflibercept and ranibizumab in the treatment of newly diagnosed neovascular age-related macular degeneration over 24 months. J Ocul Pharmacol Ther. 2017;33(7):567\u201372. https:\/\/doi.org\/10.1089\/jop.2017.0031.","journal-title":"J Ocul Pharmacol Th"},{"issue":"1","key":"4988_CR31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.oret.2018.09.001","volume":"3","author":"U Chakravarthy","year":"2019","unstructured":"Chakravarthy U, Bezlyak V, Sagkriotis A, Griner R, Skelly A, Boyer DS, et al. Effectiveness of continued ranibizumab therapy in neovascular age-related macular degeneration versus switch to aflibercept: real world evidence. Ophthalmol Retina. 2019;3(1):8\u201315.e1. https:\/\/doi.org\/10.1016\/j.oret.2018.09.001.","journal-title":"Ophthalmol Retina"},{"issue":"3","key":"4988_CR32","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1097\/IAE.0000000000001986","volume":"39","author":"TY Wong","year":"2019","unstructured":"Wong TY, Cheung CMG, Lai TYY, Chen S-J, Lee WK, Yoon YH, et al. Efficacy and safety of intravitreal aflibercept and ranibizumab in Asian patients with neovascular age-related macular degeneration: subgroup analyses from the VIEW trials. Retina. 2019;39(3):537\u201347. https:\/\/doi.org\/10.1097\/IAE.0000000000001986.","journal-title":"Retina"},{"issue":"12","key":"4988_CR33","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1016\/j.ophtha.2016.08.016","volume":"123","author":"MC Gillies","year":"2016","unstructured":"Gillies MC, Nguyen V, Daien V, Arnold JJ, Morlet N, Barthelmes D. Twelve-month outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration: data from an observational study. Ophthalmology. 2016;123(12):2545\u201353. https:\/\/doi.org\/10.1016\/j.ophtha.2016.08.016.","journal-title":"Ophthalmology"},{"issue":"8","key":"4988_CR34","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1001\/jamaophthalmol.2019.1947","volume":"137","author":"R Parikh","year":"2019","unstructured":"Parikh R, Avery RL, Saroj N, Thompson D, Freund KB. Incidence of new choroidal neovascularization in fellow eyes of patients with age-related macular degeneration treated with intravitreal aflibercept or ranibizumab. JAMA Ophthalmol. 2019;137(8):914\u201320. https:\/\/doi.org\/10.1001\/jamaophthalmol.2019.1947.","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"4988_CR35","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.ophtha.2016.03.037","volume":"123","author":"SM Waldstein","year":"2016","unstructured":"Waldstein SM, Simader C, Staurenghi G, Chong NV, Mitchell P, Jaffe GJ, et al. Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW trials. Ophthalmology. 2016;123(7):1521\u201329. https:\/\/doi.org\/10.1016\/j.ophtha.2016.03.037.","journal-title":"Ophthalmology"},{"issue":"9","key":"4988_CR36","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1016\/j.ophtha.2015.04.018","volume":"122","author":"KB Freund","year":"2015","unstructured":"Freund KB, Hoang QV, Saroj N, Thompson D. Intraocular pressure in patients with neovascular age-related macular degeneration receiving intravitreal aflibercept or ranibizumab. Ophthalmology. 2015;122(9):1802\u201310. https:\/\/doi.org\/10.1016\/j.ophtha.2015.04.018.","journal-title":"Ophthalmology"},{"key":"4988_CR37","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.2147\/OPTH.S371036","volume":"16","author":"A Rouvas","year":"2022","unstructured":"Rouvas A, Datseris I, Androudi S, Tsilimbaris M, Kabanarou SA, Pharmakakis N, et al. A real-world, multicenter, 6-month prospective study in Greece of the effectiveness and safety of ranibizumab in patients with age-related macular degeneration who have inadequately responded to aflibercept: the \u201cELEVATE\u201d study. Clin Ophthalmol. 2022;16:2579. https:\/\/doi.org\/10.2147\/OPTH.S371036.","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"4988_CR38","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1001\/jamaophthalmol.2018.6776","volume":"137","author":"MC Gillies","year":"2019","unstructured":"Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Ng P, et al. Effect of ranibizumab and aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmol. 2019;137(4):372\u201379. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.6776.","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"4988_CR39","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ophtha.2019.08.023","volume":"127","author":"MC Gillies","year":"2020","unstructured":"Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Pecheur FL, et al. Macular atrophy in neovascular age-related macular degeneration: a randomized clinical trial comparing ranibizumab and aflibercept (RIVAL study). Ophthalmology. 2020;127(2):198\u2013210. https:\/\/doi.org\/10.1016\/j.ophtha.2019.08.023.","journal-title":"Ophthalmology"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-04988-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04988-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04988-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:56:08Z","timestamp":1789437368000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-04988-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4988"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-04988-2","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"26 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics, consent to participate, and consent to publish declarations","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"573"}}